These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 27721364)

  • 1. Pediatric Dosing and Body Size in Biotherapeutics.
    Shi R; Derendorf H
    Pharmaceutics; 2010 Dec; 2(4):389-418. PubMed ID: 27721364
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Disposition and interaction of biotherapeutics in pediatric populations.
    Yanni S
    Curr Drug Metab; 2012 Sep; 13(7):882-900. PubMed ID: 22475271
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Absorption, distribution, metabolism, and excretion (ADME) studies of biotherapeutics for autoimmune and inflammatory conditions.
    Vugmeyster Y; Harrold J; Xu X
    AAPS J; 2012 Dec; 14(4):714-27. PubMed ID: 22798020
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pediatric Dose Selection for Therapeutic Proteins.
    Malik PRV; Temrikar ZH; Chelle P; Edginton AN; Meibohm B
    J Clin Pharmacol; 2021 Jun; 61 Suppl 1():S193-S206. PubMed ID: 34185910
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fixed dosing versus body size-based dosing of therapeutic peptides and proteins in adults.
    Zhang S; Shi R; Li C; Parivar K; Wang DD
    J Clin Pharmacol; 2012 Jan; 52(1):18-28. PubMed ID: 21233304
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pediatric Obesity: Pharmacokinetics and Implications for Drug Dosing.
    Kendrick JG; Carr RR; Ensom MH
    Clin Ther; 2015 Sep; 37(9):1897-923. PubMed ID: 26361823
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improving pediatric dosing through pediatric initiatives: what we have learned.
    Rodriguez W; Selen A; Avant D; Chaurasia C; Crescenzi T; Gieser G; Di Giacinto J; Huang SM; Lee P; Mathis L; Murphy D; Murphy S; Roberts R; Sachs HC; Suarez S; Tandon V; Uppoor RS
    Pediatrics; 2008 Mar; 121(3):530-9. PubMed ID: 18310202
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vancomycin dosing in children and young adults: back to the drawing board.
    Camaione L; Elliott K; Mitchell-Van Steele A; Lomaestro B; Pai MP
    Pharmacotherapy; 2013 Dec; 33(12):1278-87. PubMed ID: 24019205
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of Weight Thresholds for Pediatric Patients to Use Adult Dosage of Therapeutic Monoclonal Antibodies.
    Yang N; Xu MC; Yao Z
    J Clin Pharmacol; 2019 Oct; 59(10):1309-1318. PubMed ID: 31050000
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pediatric Obesity: Pharmacokinetic Alterations and Effects on Antimicrobial Dosing.
    Natale S; Bradley J; Nguyen WH; Tran T; Ny P; La K; Vivian E; Le J
    Pharmacotherapy; 2017 Mar; 37(3):361-378. PubMed ID: 28079262
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prediction of Pharmacokinetics and Pharmacodynamics of Doripenem in Pediatric Patients.
    Matsuo Y; Ishibashi T; Shimamura K; Wajima T
    J Pharm Sci; 2015 Sep; 104(9):3194-8. PubMed ID: 25821174
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dosing considerations in the pediatric patient.
    Skaer TL
    Clin Ther; 1991; 13(5):526-44; discussion 525. PubMed ID: 1799910
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population Pharmacokinetic Analysis of Bortezomib in Pediatric Leukemia Patients: Model-Based Support for Body Surface Area-Based Dosing Over the 2- to 16-Year Age Range.
    Hanley MJ; Mould DR; Taylor TJ; Gupta N; Suryanarayan K; Neuwirth R; Esseltine DL; Horton TM; Aplenc R; Alonzo TA; Lu X; Milton A; Venkatakrishnan K
    J Clin Pharmacol; 2017 Sep; 57(9):1183-1193. PubMed ID: 28419486
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population pharmacokinetics and pharmacokinetics/pharmacodynamics of bendamustine in pediatric patients with relapsed/refractory acute leukemia.
    Darwish M; Megason G; Bond M; Hellriegel E; Robertson P; Grasela T; Phillips L
    Curr Med Res Opin; 2014 Nov; 30(11):2305-15. PubMed ID: 25105914
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rational development and utilization of antibody-based therapeutic proteins in pediatrics.
    Xu Z; Davis HM; Zhou H
    Pharmacol Ther; 2013 Feb; 137(2):225-47. PubMed ID: 23092685
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of Dosing Strategies for Pediatric Drug Products.
    Taylor ZL; Green FG; Hossain N; Burckart GJ; Pacanowski M; Schuck RN
    Clin Pharmacol Ther; 2024 Mar; ():. PubMed ID: 38493367
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic variability in the adolescent: implications of body size and organ function for dosage regimen design.
    Rodman JH
    J Adolesc Health; 1994 Dec; 15(8):654-62. PubMed ID: 7696286
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug dosing based on weight and body surface area: mathematical assumptions and limitations in obese adults.
    Pai MP
    Pharmacotherapy; 2012 Sep; 32(9):856-68. PubMed ID: 22711238
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Population pharmacokinetic analysis of voriconazole from a pharmacokinetic study with immunocompromised Japanese pediatric subjects.
    Muto C; Shoji S; Tomono Y; Liu P
    Antimicrob Agents Chemother; 2015; 59(6):3216-23. PubMed ID: 25801557
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Medication dosing errors and associated factors in hospitalized pediatric patients from the South Area of the West Bank - Palestine.
    Al-Ramahi R; Hmedat B; Alnjajrah E; Manasrah I; Radwan I; Alkhatib M
    Saudi Pharm J; 2017 Sep; 25(6):857-860. PubMed ID: 28951670
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.